AZD5634 for inhalation + AZD5634 for infusion
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Feb 11, 2016 → Oct 24, 2016
NCT ID
NCT02679729About AZD5634 for inhalation + AZD5634 for infusion
AZD5634 for inhalation + AZD5634 for infusion is a phase 1 stage product being developed by AstraZeneca for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02679729. Target conditions include Cystic Fibrosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02679729 | Phase 1 | Completed |
Competing Products
20 competing products in Cystic Fibrosis